Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Accellacare

Neither a doctor nor a teaching hospital

Research payments

$4,510,763

893 payments

Through program year 2025, Accellacare is reported as receiving $4,510,763 in research payments, across 893 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $3,688,786 88
2024 Research $289,079 71
2023 Research $266,380 577
2022 Research $264,567 154
2021 Research $1,951 3

Breakdown

Who paid Research payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $3,369,858 29 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $375,224 30 payments
  3. Janssen Research & Development, LLC $210,519 70 payments
  4. GlaxoSmithKline, LLC. $199,836 1 payment
  5. Novo Nordisk AS $184,150 703 payments
  6. Novartis Pharmaceuticals Corporation $47,779 2 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $32,412 9 payments
  8. Pfizer Inc. $31,228 27 payments
  9. AstraZeneca UK Limited $26,206 4 payments
  10. Becton, Dickinson and Company $15,426 1 payment
Studies the money was for Research payments · program years 2021–2025
  1. A Phase IIb Randomized Double blind Placebo controlled and Open label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus $1,392,882 6 payments
  2. A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Participants living with Obesity or Overweight with Comorbidity $1,074,558 5 payments
  3. A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 in Participants Living with Obesity or Overweight with Comorbidity $697,820 2 payments
  4. A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus $231,706 16 payments
  5. A Phase I/II Observer-Blind, Randomized, Placebo Controlled, Multi-Cen $199,836 1 payment
  6. Nn9535-4801 $184,150 703 payments
  7. A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes $143,517 14 payments
  8. A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) $126,251 4 payments
  9. A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome pSS $81,535 13 payments
  10. Cnto1959pso3018 $78,655 20 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record